Intech Investment Management LLC Has $7.54 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Intech Investment Management LLC grew its stake in Thermo Fisher Scientific Inc. (NYSE:TMO) by 33.5% during the second quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 18,588 shares of the medical research company’s stock after purchasing an additional 4,662 shares during the quarter. Intech Investment Management LLC’s holdings in Thermo Fisher Scientific were worth $7,537,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also added to or reduced their stakes in TMO. CBIZ Investment Advisory Services LLC grew its position in shares of Thermo Fisher Scientific by 137.5% during the 1st quarter. CBIZ Investment Advisory Services LLC now owns 57 shares of the medical research company’s stock worth $28,000 after buying an additional 33 shares during the period. Anderson Financial Strategies LLC bought a new position in Thermo Fisher Scientific during the 1st quarter worth approximately $30,000. Keystone Global Partners LLC acquired a new position in Thermo Fisher Scientific during the first quarter valued at approximately $31,000. DiNuzzo Private Wealth Inc. raised its holdings in Thermo Fisher Scientific by 406.7% in the second quarter. DiNuzzo Private Wealth Inc. now owns 76 shares of the medical research company’s stock worth $31,000 after purchasing an additional 61 shares during the period. Finally, HighMark Wealth Management LLC boosted its position in shares of Thermo Fisher Scientific by 140.6% during the second quarter. HighMark Wealth Management LLC now owns 77 shares of the medical research company’s stock worth $31,000 after purchasing an additional 45 shares in the last quarter. Institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Price Performance

Shares of TMO opened at $579.12 on Monday. The company has a quick ratio of 1.11, a current ratio of 1.50 and a debt-to-equity ratio of 0.62. Thermo Fisher Scientific Inc. has a twelve month low of $385.46 and a twelve month high of $610.97. The stock has a market capitalization of $217.58 billion, a P/E ratio of 33.46, a P/E/G ratio of 3.27 and a beta of 0.82. The company has a 50 day moving average of $527.90 and a 200-day moving average of $468.32.

Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, October 22nd. The medical research company reported $5.79 EPS for the quarter, topping the consensus estimate of $5.50 by $0.29. Thermo Fisher Scientific had a net margin of 15.02% and a return on equity of 16.97%. The business had revenue of $11.12 billion during the quarter, compared to analysts’ expectations of $10.90 billion. During the same quarter in the prior year, the company posted $5.28 earnings per share. The firm’s revenue was up 4.9% on a year-over-year basis. Thermo Fisher Scientific has set its FY 2025 guidance at 22.600-22.860 EPS. As a group, equities research analysts forecast that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, January 15th. Investors of record on Monday, December 15th will be issued a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a yield of 0.3%. The ex-dividend date is Monday, December 15th. Thermo Fisher Scientific’s dividend payout ratio is presently 9.94%.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase program on Thursday, November 6th that permits the company to buyback $5.00 billion in outstanding shares. This buyback authorization permits the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback programs are often a sign that the company’s board of directors believes its shares are undervalued.

Analysts Set New Price Targets

Several analysts recently commented on the company. Leerink Partners raised their price objective on Thermo Fisher Scientific from $545.00 to $580.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 22nd. UBS Group raised their price target on Thermo Fisher Scientific from $500.00 to $590.00 and gave the stock a “neutral” rating in a research report on Thursday, October 23rd. Robert W. Baird lifted their price objective on Thermo Fisher Scientific from $553.00 to $567.00 and gave the company an “outperform” rating in a report on Thursday, July 24th. Raymond James Financial restated an “outperform” rating and set a $535.00 target price (up from $525.00) on shares of Thermo Fisher Scientific in a report on Thursday, July 24th. Finally, Wall Street Zen upgraded shares of Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Saturday, October 25th. Nineteen investment analysts have rated the stock with a Buy rating and five have given a Hold rating to the company. Based on data from MarketBeat.com, Thermo Fisher Scientific currently has an average rating of “Moderate Buy” and an average target price of $601.65.

Insider Activity

In related news, CEO Marc N. Casper sold 17,104 shares of the firm’s stock in a transaction on Friday, October 24th. The shares were sold at an average price of $573.54, for a total value of $9,809,828.16. Following the completion of the transaction, the chief executive officer directly owned 113,762 shares of the company’s stock, valued at approximately $65,247,057.48. This trade represents a 13.07% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, COO Michel Lagarde sold 4,638 shares of the company’s stock in a transaction on Thursday, November 13th. The stock was sold at an average price of $594.42, for a total transaction of $2,756,919.96. Following the sale, the chief operating officer directly owned 23,480 shares in the company, valued at $13,956,981.60. This trade represents a 16.49% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 52,341 shares of company stock valued at $29,204,998. Corporate insiders own 0.33% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.